Physicochemical Properties
| Molecular Formula | C51H73N13O14 |
| Molecular Weight | 1092.222 |
| Exact Mass | 1031.518 |
| Elemental Analysis | C, 56.08; H, 6.74; N, 16.67; O, 20.51 |
| CAS # | 58-49-1 |
| PubChem CID | 9811952 |
| Appearance | White to off-white solid powder |
| LogP | 2.77 |
| Hydrogen Bond Donor Count | 13 |
| Hydrogen Bond Acceptor Count | 15 |
| Rotatable Bond Count | 28 |
| Heavy Atom Count | 74 |
| Complexity | 1960 |
| Defined Atom Stereocenter Count | 8 |
| SMILES | NC(NCCC[C@H](NC([C@@H](N)CC(O)=O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=C(O)C=C1)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CN=CN1)C(N1[C@H](C(N[C@@H](CC2=CC=CC=C2)C(O)=O)=O)CCC1)=O)=O)=O)=O)=O)=N.CC(O)=O |
| InChi Key | JVCJXRGXGITABA-IAQGTVMASA-N |
| InChi Code | InChI=1S/C49H69N13O12.C2H4O2/c1-26(2)39(60-42(67)33(12-8-18-54-49(51)52)56-41(66)32(50)23-38(64)65)45(70)57-34(20-29-14-16-31(63)17-15-29)43(68)61-40(27(3)4)46(71)58-35(22-30-24-53-25-55-30)47(72)62-19-9-13-37(62)44(69)59-36(48(73)74)21-28-10-6-5-7-11-28;1-2(3)4/h5-7,10-11,14-17,24-27,32-37,39-40,63H,8-9,12-13,18-23,50H2,1-4H3,(H,53,55)(H,56,66)(H,57,70)(H,58,71)(H,59,69)(H,60,67)(H,61,68)(H,64,65)(H,73,74)(H4,51,52,54);1H3,(H,3,4)/t32-,33-,34-,35-,36-,37-,39-,40-;/m0./s1 |
| Chemical Name | (2S,5S,8S,11S,14S,17S)-2-((1H-imidazol-4-yl)methyl)-17-amino-1-((S)-2-(((S)-1-carboxy-2-phenylethyl)carbamoyl)pyrrolidin-1-yl)-14-(3-guanidinopropyl)-8-(4-hydroxybenzyl)-5,11-diisopropyl-1,4,7,10,13,16-hexaoxo-3,6,9,12,15-pentaazanonadecan-19-oic acid compound with acetic acid (1:1) |
| Synonyms | Human Angiotensin II Acetate Salt; Val5-ANG II; H-Asp-Arg-Val-Tyr-Val-His-Pro-Phe-OH; Angiotensin acetate; (Val5)-Angiotensin II |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | Angiotensin receptor |
| ln Vivo | Angiotensin II 5-valine infusion resulted in a significant increase in systolic blood pressure (SBP) by day 12 (197 ± 7 mm Hg). Losartan may prevent the development of hypertension associated with ANG II infusion. Blood and kidney samples were collected, HPLC was performed to separate angiotensin II 5-valine (exogenous) from Ile5-ANG II (endogenous), and the fractions were measured by radioimmunoassay. In the angiotensin II 5-valine infusion construct that received losartan treatment, total ANG II levels increased to a greater extent than in the waveform that did not receive lossartan treatment (289 ± 20 v 119 ± 14 fmol/ mL). However, Losartan significantly reduced the enhancement of renal Val5-ANG II content by 88%, and this enhancement occurred only in the specific gravity of Val5-ANG II [1]. |
| References |
[1]. Renal uptake of circulating angiotensin II in Val5-angiotensin II infused rats is mediated by AT1 receptor. Am J Hypertens. 1998 May;11(5):570-8. |
| Additional Infomation | Val(5)-angiotensin II is an angiotensin II. |
Solubility Data
| Solubility (In Vitro) | H2O: ~100 mg/mL (~96.9 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 33.33 mg/mL (32.29 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9156 mL | 4.5778 mL | 9.1557 mL | |
| 5 mM | 0.1831 mL | 0.9156 mL | 1.8311 mL | |
| 10 mM | 0.0916 mL | 0.4578 mL | 0.9156 mL |